← Back to Home

Huyabio International

Private
#Melanoma#Oncology#Hematologic Malignancies

Huyabio International is a clinical-stage biopharmaceutical company developing novel small molecule oncology therapeutics. Lead program HBI-8000 (tucidinostat) is an HDAC inhibitor that has demonstrated Phase 3 success in melanoma and is approved in China for multiple oncology indications.

Company Info

Sector:Oncology / HDAC Inhibitors
Headquarters:San Diego, California, USA
Founded:2008
Website:huyabio.com/
Funding Round:Series D
Total Funding:See company disclosures

Funding & Investor Relations

IPO Outlook / Plans

Pre-IPO; no announced timeline

Upcoming Milestones & Key Dates

2026-Q4
Regulatory

FDA NDA filing for HBI-8000 in melanoma

Clinical Development Pipeline

HBI-8000 (tucidinostat)

Target: HDAC class I
Metastatic melanoma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

HBI-8000 (tucidinostat)

Target: HDAC class I
PTCL (China-approved)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

HBI-3000

Target: Undisclosed
Solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Dr. Ge Wei

CEO

TBD

Chief Medical Officer

TBD

Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments
San Diego, California, USA
Apply Now →